ERBB2 and breast carcinoma: Our findings indicate that persistent or increased expression of CD44v positive cancer cells, or an increase in the expression level of CD44v after 6 weeks of lapatinib and trastuzumab therapy may predict unsuccessful induction of pCR in breast cancer patients treated with preoperative dual anti-HER2 therapy and concurrent cytotoxic chemotherapy.